Is CD1a involved in antitumour immune responses during carcinogenesis?

Cappello, Francesco

doi:10.1038/sj.bjc.6601597

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, CD1a protein has been found to be expressed in metaplastic epithelial cells of Barrett's esophagus, (an acquired metaplastic condition of the distal esophagus characterised by the replacement of the normal squamous epithelium by a columnar epithelium), both gastric and intestinal types, but not in normal epithelium of gastric and intestinal mucosae [25,26].…”

Section: Unclear Expression Of Cd1a By Epithelial Cellsmentioning

confidence: 99%

CD1a and antitumour immune response

et al. 2004

View full text Add to dashboard Cite

Section: Unclear Expression Of Cd1a By Epithelial Cellsmentioning

confidence: 99%

CD1a and antitumour immune response

et al. 2004

View full text Add to dashboard Cite

“…We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003). In particular, we postulated that this marker may be useful in diagnosing Barrett's metaplasia (BM) and we hypothesised that its expression could predict a favourable outcome of this disease (Cappello, 2004).Indeed, BM may evolve towards dysplasia (Dy) or carcinoma (Ca) (Cameron and Carpenter, 1997; Malhi-Chowla et al, 2000;Moreto, 2003). Nevertheless, to date, we do not have any marker that could help to predict BM evolution.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer

et al. 2005

Self Cite

View full text Add to dashboard Cite

As emerging in the recent literature, CD1a has been regarded as a molecule whose expression may reflect tumour evolution. The aim of the present work was to investigate the expression of CD1a in a series of Barrett's metaplasia (BM), gastric type (GTBM), with and without follow-up, in order to analyse whether its expression may help to diagnose this disease and to address the outcome. Indeed, GTBM may be confused sometimes with islets of ectopic gastric mucosa and its evolution towards dysplasia (Dy) or carcinoma (Ca) could not be foreseen. We showed a significant higher expression of CD1a in GTBM than in both Dy and Ca; nevertheless, the number of positive GTBM was significantly lower in the group of cases that at follow-up underwent Dy or Ca. Our data address that CD1a may be a novel biomarker for BM and that its expression may help to predict the prognosis of this pathology. CD1a is a surface glycoprotein of 43 -49 kDa that has been shown to be expressed by dendritic cells (DCs), cortical thymocytes and Langerhans cells of the skin (Dezutter-Dambuyant et al, 1990;Krenacs et al, 1993;Gregory et al, 2000). Moreover, the research of CD1a is commonly used to differentiate various cutaneous T-cell lymphomas from B-cell lymphomasand pseudolymphomas (Arai et al, 1999;Schmuth et al, 2001).The antitumoral role of CD1a was recently proposed (Coventry and Morton, 2003a;Coventry and Heinzel, 2004;La Rocca et al, 2004). We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003). In particular, we postulated that this marker may be useful in diagnosing Barrett's metaplasia (BM) and we hypothesised that its expression could predict a favourable outcome of this disease (Cappello, 2004).Indeed, BM may evolve towards dysplasia (Dy) or carcinoma (Ca) (Cameron and Carpenter, 1997; Malhi-Chowla et al, 2000;Moreto, 2003). Nevertheless, to date, we do not have any marker that could help to predict BM evolution.The aim of the present work was to detect CD1a expression in a large series of BM, Dy and Ca at the time of diagnosis and at follow-up. We would verify the diagnostic role of CD1a for BM and confirm our hypothesis concerning its prognostic role. MATERIALS AND METHODS Sample collectionWe selected retrospectively from our files, 222 cases as follows: 166 specimens were BM of gastric type (GTBM) that underwent follow up; moreover, we selected 37 specimens of Dy and 19 of Ca that did not undergo follow-up. Finally, as control group, we selected 10 specimens from normal gastric mucosa. Sample collection was performed according to ethical standards. In addition, we collected, from the 166 cases of GTBM, the specimens that underwent follow-up, commonly between 12 and 36 months from first diagnosis; in 134 cases, the diagnosis of BM was confirmed (FU-GTBM), while in 23 cases, GTBM evolved towards dysplasia (FU-Dy) and in nine cases towards carcinoma (FU-Ca). Imm...

show abstract

Is CD1a involved in antitumour immune responses during carcinogenesis?

Cited by 2 publications

References 3 publications

CD1a and antitumour immune response

CD1a and antitumour immune response

CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer

Contact Info

Product

Resources

About